A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer

CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

(2021) Michael McDonald et al.   CANADIAN JOURNAL OF CARDIOLOGY

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer

(2019) Maya Guglin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

(2019) Xavier Pivot et al.   EUROPEAN JOURNAL OF CANCER

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity

(2018) Mônica Samuel Avila et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity

(2017) Maryam Nabati et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity

(2017) Edith Pituskin et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer

(2017) Saranrat Wittayanukorn et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Trastuzumab cardiotoxicity: from clinical trials to experimental studies

(2016) Balazs T Nemeth et al.   BRITISH JOURNAL OF PHARMACOLOGY

Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial

(2016) Ahmad Tashakori Beheshti et al.   CARDIOLOGY

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

(2016) Geeta Gulati et al.   EUROPEAN HEART JOURNAL

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer

(2016) Annelies H. Boekhout et al.   JAMA Oncology

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

(2015) D. Cardinale et al.   CIRCULATION

Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change

(2014) John E. Cornell et al.   ANNALS OF INTERNAL MEDICINE

Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up

(2013) Ali Elitok et al.   Cardiology Journal

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study

(2012) Mehmet G. Kaya et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE